BIOMAT Database Logo BIOMAT Database Logo

High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients. 1993

E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Department of Pharmacy, University of Illinois, Chicago 60612.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003365 Costs and Cost Analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs. Affordability,Analysis, Cost,Cost,Cost Analysis,Cost Comparison,Cost Measures,Cost-Minimization Analysis,Costs and Cost Analyses,Costs, Cost Analysis,Pricing,Affordabilities,Analyses, Cost,Analyses, Cost-Minimization,Analysis, Cost-Minimization,Comparison, Cost,Comparisons, Cost,Cost Analyses,Cost Comparisons,Cost Measure,Cost Minimization Analysis,Cost, Cost Analysis,Cost-Minimization Analyses,Costs,Measure, Cost,Measures, Cost
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic

Related Publications

E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.
May 1991, Antimicrobial agents and chemotherapy,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
February 1995, Transplantation proceedings,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients.
January 2018, The Annals of pharmacotherapy,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients.
February 1996, Journal of the American Society of Nephrology : JASN,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Failure of acyclovir to prevent cytomegalovirus infection in renal allograft recipients.
January 1993, Transplant international : official journal of the European Society for Organ Transplantation,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits.
August 1998, Transplantation proceedings,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients.
September 1993, The Journal of infectious diseases,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
December 1996, Kidney international. Supplement,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Cytomegalovirus infection among renal allograft recipients.
January 1969, Acta medica Scandinavica,
E M Vasquez, and J Sanchez, and R Pollak, and D Vrahnos, and A J Fabrega, and M S Maddux
Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir.
December 1985, JAMA,
Copied contents to your clipboard!